Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jul
15
Today In Oncology
Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC
KRAS G12D–Mutated Metastatic Pancreatic Cancer Zoldonrasib Plus Chemotherapy
Over 50 Million Americans Live in Counties Without a Radiation Oncology Clinic
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo